Travere Therapeutics, Inc. reports developments in rare-disease biopharmaceuticals, with recurring updates on FILSPARI (sparsentan), FDA regulatory actions, commercialization in IgA nephropathy and focal segmental glomerulosclerosis, and financial results. The company focuses on therapies for rare kidney, liver, and metabolic diseases, including sparsentan and the investigational enzyme replacement therapy pegtibatinase.
Company news also covers clinical data presentations, partner-related regulatory and commercial milestones for sparsentan, capital-structure activity, inducement equity grants under Nasdaq rules, and investor-conference participation.
Travere Therapeutics (TVTX) will present new FILSPARI clinical data for two rare kidney diseases at ASN Kidney Week 2026. The program includes nine presentations, five oral, in Denver on October 21–25.
In the Phase 2 SPARTAN IgA nephropathy study, 75% achieved complete proteinuria remission, meaning very low urine protein, at any time during treatment. The least-squares mean change in estimated kidney filtration rate (eGFR) was −1.75 mL/min/1.73 m² at week 110.
A post hoc analysis of 254 patients with focal segmental glomerulosclerosis without nephrotic syndrome in Phase 3 DUPLEX found complete remission in 20% receiving FILSPARI versus 6% receiving maximum labeled dose irbesartan. Kidney failure occurred in 2% versus 8%, respectively. Treatment-emergent adverse event rates were comparable at 92% versus 94%.
Travere Therapeutics (TVTX) received a Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application No. 19/253,120 covering certain methods of using FILSPARI (sparsentan) in focal segmental glomerulosclerosis (FSGS).
Upon issuance, the patent is expected to provide U.S. protection for these FSGS use methods into October 2037, following payment of the issue fee and standard post-allowance processing. Travere plans to submit the granted patent for listing in the FDA’s Orange Book. In August 2026, the company also obtained a separate U.S. patent covering certain methods of using sparsentan in IgA nephropathy (IgAN). The release reiterates FILSPARI’s approved U.S. indications and detailed safety information, including its boxed warnings and REMS requirements.
Travere Therapeutics (TVTX) announced a planned CEO transition, with Eric Dube stepping down and Bradley Campbell becoming president and chief executive officer on December 1, 2026.
Dube, who has led the company since January 2019, is leaving the CEO role to focus on his health and family and will remain employed as executive advisor through February 15, 2027 to support an orderly handover. Under his leadership, Travere gained regulatory approvals in IgA nephropathy and focal segmental glomerulosclerosis (including the first approved medicine for FSGS), expanded its rare disease pipeline and capabilities, and strengthened a patient-centered culture.
The Board unanimously selected Campbell, former president and CEO of Amicus Therapeutics (now a BioMarin subsidiary), citing his scientific, commercial and operational experience in rare diseases, his record of scaling therapies and advancing clinical pipelines, and his role in growing Amicus from a single-product to a multi-franchise global rare disease organization.
Travere Therapeutics (TVTX) will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at 10:30 a.m. ET.
A live webcast of the presentation will be available on the Investor page of Travere’s website at ir.travere.com/events-and-presentations, with a replay accessible for up to 30 days after the event.
Travere Therapeutics (TVTX) reported that on September 10, 2026, its Board Compensation Committee approved inducement restricted stock unit (RSU) awards for 16 new employees, covering a total of 56,220 shares of common stock. The RSUs, granted as employment inducements under Nasdaq Listing Rule 5635(c)(4), were made outside the company’s 2018 Equity Incentive Plan but are subject to its terms. The awards vest over four years, with 25% of the shares vesting on each anniversary of the grant date, contingent on continued service.
Travere Therapeutics (Nasdaq: TVTX) reported that on August 10, 2026, its Board Compensation Committee approved inducement restricted stock unit (RSU) grants for 12 new employees, covering an aggregate of 38,940 shares of common stock. The RSUs were granted outside the company’s 2018 Equity Incentive Plan as employment inducements under Nasdaq Listing Rule 5635(c)(4). They vest over four years, with 25% of each award vesting on every anniversary of the grant date, contingent on the employee’s continued service.
Travere Therapeutics (Nasdaq: TVTX) will participate in several investor conferences, including Canaccord Genuity's 46th Annual Growth Conference on August 11, 2026, the Wells Fargo 21st Annual Healthcare Conference on September 8, 2026, the Citi 2026 Biopharma Back to School Conference on September 9, 2026, and the 2026 Cantor Global Healthcare Conference on September 10, 2026. Live webcasts and 30-day replays will be available on Travere’s investor website.
Travere Therapeutics (Nasdaq: TVTX) reported second quarter 2026 U.S. net product sales of $161.4 million, up from $94.8 million a year ago, driven by FILSPARI U.S. net product sales of $141.1 million, a 96% year-over-year increase, supported by 2,012 new patient start forms from FSGS launch and continued IgAN growth.
GAAP net loss was $34.8 million ($0.37 per share) versus $12.8 million in 2025, impacted by a $40 million inducement expense tied to 2029 convertible note repurchases. Non-GAAP net loss was $9.0 million. Cash, cash equivalents and marketable securities totaled $489.2 million post May 2026 convertible note transactions.
R&D expenses rose to $60.3 million and SG&A to $96.1 million, reflecting pegtibatinase Phase 3 HARMONY progress and FILSPARI commercialization. Travere also in-licensed civorebrutinib from Everest Medicines, paying a $112.5 million upfront in July 2026, and advanced FILSPARI and pegtibatinase clinical programs, with key readouts expected between 2026 and 2027.
Travere Therapeutics (Nasdaq: TVTX) announced it will report its second quarter 2026 financial results on Tuesday, August 4, 2026, after the U.S. market close. The company will host a conference call and webcast at 4:30 p.m. ET, with access and a 30-day replay via its investor website.
Travere Therapeutics (Nasdaq: TVTX) reported that on July 10, 2026, its Board Compensation Committee approved Nasdaq Rule 5635(c)(4) inducement equity grants for six new employees, totaling 41,600 shares, split into 18,000 stock options and 23,600 RSUs with four-year vesting schedules.